StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)

Close on Nov 17, 2026Market cap $39.19MP/E –Yield –

Scribe Therapeutics cash

Cash and short-term investments held at the end of each period.

Scribe Therapeutics's cash was $43.00M at Jun 30, 2026. For fiscal 2025 it was $58.00M, up 336.8% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$58.00M+336.8%
FY2024Dec 31, 2024$13.28M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$43.00M–
Q4 FY2025Dec 31, 2025$58.00M–
Q2 FY2025Jun 30, 2025$16.66M–
Q4 FY2024Dec 31, 2024$13.28M–

More Scribe Therapeutics figures

See a number that looks wrong?